mercredi 13 juin 2018

Onco Actu du 13 juin 2018

1. Biologie

Genetic discovery will help clinicians identify aggressive versus benign bone tumours [Sanger Institute]

1.4 Biologie - Technos

Genome-editing tool could increase cancer risk [Karolinska Institutet]

2 studies show CRISPR might drive up cancer risk in edited cells [FierceBiotech]

A Crispr Conundrum: How Cells Fend Off Gene Editing [NY Times]

2. Etiologie

Do Sunscreens Cause Cancer? [Science-Based Medicine]

2.5 Etiologie - Gènes

OncoArray Links Dozens of DNA Variants to Risk for Common Cancers [NCI]

2.6 Etiologie - Environnement

How to Kill Dialogue [The Risk-Monger]

4.1 Dép., diag. & prono. - Prostate

New genetic variations identify men at higher risk of prostate cancer [NHS Choices]

5.10 Traitements - Essais

PARP inhibitor improves overall response rates in small cell lung cancer patients [MD Anderson Cancer Center]

Avoidable waste of research related to outcome planning and reporting in clinical trials [BMC Medicine]

5.12 Immunothérapies

Discovery of Unusual Cell Type Could Help Guide Immunotherapy [Memorial Sloan Kettering Cancer Center]

5.12.2 Immunothérapies - CAR-T, thérapies cellulaires

Cellectis Publishes Novel Methods to Improve the Clinical Use of Chimeric Antigen Receptor T-Cell Therapy in Scientific Reports [Cellectis]

Cellectis, rising star Allogene design an ‘all-in-one’ CAR construct with embedded safety switch as the new partners angle for the clinic [EndPoints]

5.12.6 Immunothérapies - AMM

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Previously Treated Patients with Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS Greater Than or Equal to 1) [Merck]

5.2 Pharma

Consolidate pRED and gRED R&D units? ‘No way,’ says Roche CEO [FierceBiotech]

Sanofi says back on track to regain solid position in cancer drugs [Reuters]

Roche CEO Severin Schwan isn’t about to tamper with a winning R&D strategy now, but he’s still looking for ways to cut costs [EndPoints]

5.3 Traitements - FDA, EMA, NICE...

Statement from FDA Commissioner Scott Gottlieb, M.D., on new efforts to advance medical product communications to support drug competition and value-based health care [FDA]

Statement from FDA Commissioner Scott Gottlieb, M.D., on new agency efforts to advance the patient voice in medical product development and FDA regulatory decision-making [FDA] ASCO (médecine de précision-sein)

Most Women with Early-Stage Breast Cancer Don’t Need Chemo [NIH Director's Blog]

6.10.1 Politiques (USA)

No Price Cuts Yet, But Azar Urges Congress to Target Drug Rebates & Transparency [Xconomy]

6.7 DMP, Big Data & applis

Why are fax machines still the norm in 21st-century health care? [The Globe and Mail]

6.8 Communication

Cancer misinformation in various media irks breast cancer patients in US & UK [HealthNewsReview]

6.9 Controverses

Prominent biologist resigns from top US institute after harassment allegations [Nature]